Kaiseraugst (CH) | Heerlen (NL). (dsf) DSM-Firmenich AG reported its financial results for the third quarter 2023. Q3-2023 financial and operational highlights:
- Perfumery + Beauty performed well and Taste, Texture + Health was resilient
- Health, Nutrition + Care, and Animal Nutrition + Health were weak, driven by record low vitamin prices
- Cash flow prioritized, resulting in an improved cash conversion ratio of 56 percent
- Vitamin transformation and EUR 200 million cost reduction program well under way
- Merger integration process progressing well, with synergy delivery in line with plan
- FY 2023 outlook: Adjusted Ebitda of around EUR 1,800 million
Chief Executives Statement
Chief Executive Dimitri de Vreeze says in his summary: «In the current global economic environment we are working hard to mitigate the effects through strong internal actions. To this end, we are driving a broad range of self-help measures, with the largest contributor being the vitamin transformation program. In addition, we have pushed harder on cash flow, a key priority for us, and see good improvements this quarter. At the same time, we remain relentlessly focused on the successful integration of the merger and the delivery of our targeted synergies.
«During the quarter we were pleased with the continued good performance of our Perfumery + Beauty and the resilience of our Taste, Texture + Health businesses. However, destocking continued, and vitamin prices remained under pressure, impacting particularly Animal Nutrition + Health and Health, Nutrition + Care businesses. For the remainder of the year, we do not expect a material change in these business conditions, although the last quarter will begin to reflect the contribution from our internal costs actions.
«The decisive actions we are taking at this time provide a strong base from which we will be able to deliver attractive innovation-driven growth. With our market-leading and highly complementary portfolio of ingredients, science and technologies, we are confident in achieving our mid-term financial targets. We are reviewing all segments to prioritize and accelerate the company’s high growth and higher margin business. We will provide an update on progress of all our strategic actions at our Capital Markets Day next year.»
Outlook 2023
The company estimates for FY 2023, on a pro forma basis, an Adjusted Ebitda of around EUR 1,800 million, which includes an estimated negative vitamin effect of about EUR 500 million as well as a negative foreign exchange effect of about EUR 90 million. For additional info please read the PDF file below (157 KB):
20231128-DSM-FIRMENICH-Q3-2023.OTHER TOPICS FROM THIS SECTION FOR YOU:
- Nestle S.A.: reports half-year results for 2024
- PepsiCo: Reports Second-Quarter 2024 Results
- Oatly AB: Reports Second Quarter 2024 Financial Results
- Grupo Bimbo: Reports Second Quarter 2024 Results
- Gruma: reports second quarter 2024 results
- Reborn Coffee: Provides Q1-2024 Corporate Update
- Coca-Cola: Reports Second Quarter 2024 Financial Results
- Krispy Kreme: Sells Majority Stake of Insomnia Cookies
- Dominos: Announces Q2-2024 Financial Results
- Reborn Coffee takes over Korean Bbang Ssaem Bakery
- SSP Group: announces Third Quarter Trading Update 2024
- LG Chem and ADM: Joint Ventures in Illinois are canceled
- Wendy’s: Company plans to expand into Europe
- Delivery Hero: may face significant fine due to antitrust violations
- Emmi Group: intends to acquire Mademoiselle Desserts
- AB Foods: announces strong H1-2024 performance
- DSM-Firmenich: Queen Maxima inaugurates new dual head office
- RBI: Announces Investments to Drive Growth in China
- Europastry S.A.: puts its IPO process on hold
- McCormick: Reports Second Quarter Performance